Insights

Professional
Practice
Industry
Region
Trending Topics
Location
Type

Sort by:

Firm News 33 results

Firm News | 3 min read | 08.08.24

Crowell & Moring Partners Preston L. Pugh and Keith J. Harrison Named to Savoy’s List of “Most Influential Lawyers”

Savoy named Crowell & Moring partners Preston L. Pugh and Keith J. Harrison to its 2024 list of “Most Influential Lawyers.” According to the publication, this award honors powerhouse lawyers “whose legal prowess and commitment to excellence inspire the highest levels of corporate and legal leadership.”

Firm News | 2 min read | 08.07.24

Florida Court Rules State Does Not Need to Correct Miscalculation of Crosley Green’s Parole Date That Could Cost Him 40 Years of His Life

A Florida court ruled last week that the Florida Commission on Offender Review does not have to reset Crosley Green’s eligible parole date or correct a miscalculation that arbitrarily added more than 40 years to his imprisonment. The Circuit Court for Florida’s 2ndJudicial Circuit denied Mr. Green’s writ of mandamus seeking to compel the Commission to correct a 2015 error that set his presumptive parole release date (PPRD) to 2054, when he is 97 years old, or to calculate a new PPRD in accordance with Florida law. Under Florida law, Mr. Green should be eligible for parole now.

Firm News | 3 min read | 04.18.24

On the Anniversary of His Return to Imprisonment, Crosley Green’s Lawyers Ask a Florida Court to Correct the Miscalculation that Could Cost Him 40 Years of His Life

On the one-year anniversary of Crosley Green’s return to prison for a murder he did not commit, after previously serving more than 30 years, lawyers for Mr. Green asked a Florida court to order the Florida Commission on Offender Review to correct the miscalculation of his eligible parole date. They argue that the Commission arbitrarily added more than 40 years to Mr. Green’s sentence, contrary to Florida law.

Client Alerts 25 results

Client Alert | 2 min read | 07.12.19

DOJ's Dilemma: Granston Motions are on the Rise… But Not Always Met with Swift Justice

On July 3, 2019, in United States ex rel. Johnson v. Raytheon Co., the U.S. District Court for the Northern District of Texas granted the government’s motion to dismiss a qui tam suit over the objections of the relator. The Johnson case is just the latest example of the Department of Justice (DOJ) using its authority under Section 3730(c)(2)(A) of the False Claims Act to seek dismissal of meritless qui tam suits, consistent with a January 2018 DOJ Memorandum emphasizing the importance of that authority (the “Granston memo”).
...

Client Alert | 5 min read | 12.21.18

DOJ Moves to Dismiss Ten Kickback-Related False Claims Act Complaints Against Pharmaceutical Companies

On Monday, DOJ moved to dismiss ten kickback-related FCA complaints against thirty-eight major pharmaceuticals companies and commercial-outsourcing vendors. The number of motions is striking in itself, because DOJ has rarely used that authority in the past, moving to dismiss approximately thirty FCA cases from 1986 to 2011. Monday’s filings reinforce a trend of increased dismissals since the Granston Memo. And they follow on the heels of a high-profile announcement that DOJ is prepared to seek dismissal in Gilead Sciences, Inc. v. United States ex rel. Campie, on which we reported here. The motions demonstrate that the Granston Memo has teeth and suggest a narrower interpretation of the Anti-Kickback Statute that may offer some relief to the pharmaceutical industry, which has long been a primary target of FCA enforcement.
...

Client Alert | 2 min read | 07.11.16

Dancing Doesn’t Matter – Federal Circuit Said Biosimilar Companies Must Wait 180 Days

Last Tuesday, the Federal Circuit unanimously held that all biosimilar companies – even companies that participate in the so called “patent dance” – must notify brand-name rivals of their intent to sell a biosimilar drug 180 days before marketing the drug. The case, Amgen Inc., v. Apotex Inc. could have major implications for the timing of when biosimilar companies launch their drugs.
...

Press Coverage 102 results

Publications 9 results

Publication | 01.09.19

Jurisdictional Analysis – Time to Trial, Favorable Courts & Other Litigation Trends

Crowell & Moring's Litigation Forecast 2019
Several litigation trends set in motion by recent  events continued in 2018 and have now become the “new normal.” In 2018, D. Delaware, as predicted, overtook E.D. Texas for the largest number of patent cases filed, a trend set in motion by the May 2017 Supreme Court decision in T.C. Heartland, which made personal jurisdiction for corporations a driving force in patent litigation forum selection. Another continuing trend: trade secret litigation has skyrocketed—tripled since 2016. This is no anomaly. Macro trends like the digitization of intellectual property, surging employee mobility, and reduced patent protection for software and business methods have combined with the Defend Trade Secrets Act of 2016 to make trade secret litigation an increasingly popular and effective tool for protecting high-tech assets. D. New Jersey has the most product liability filings, in large part due to the Johnson & Johnson Talcum Powder Products Liability Litigation multidistrict litigation (MDL) filed in the last months of 2017. But D. New Jersey is also the most frequent venue for non-MDL medical device and pharmaceutical product cases, due to the large number of device and drug manufacturers headquartered in that venue, again based on T.C.Heartland.
...

Publication | 01.09.18

Jurisdictional Analysis – Time to Trial, Favorable Courts & Other Litigation Trends

Crowell & Moring's Litigation Forecast 2018
While past events are no guarantee of the future, certain litigation trends can be useful barometers. For example, the national downward trend for patent litigation has continued since the advent of the America Invents Act. But while the overall trend is downward, E.D. Texas still maintains its place as the most popular location for new patent cases—at least for now. But that trend may not hold. Patent case filings in D. Delaware have exploded due to the Supreme Court’s May 2017 decision in TC Heartland, and Delaware is now a close second to E.D. Texas. N.D. California also saw a dramatic rise in patent filings. Instead of flocking to E.D. Texas, patent owners are pivoting to D. Delaware and N.D. California, where venue can be established based on corporate headquarters. While E.D. Texas may still have more total IP filings due to its pre-TC Heartland head start, since that decision, Delaware has had the most filings and that trend will continue. Another trend is the dramatic increase in antitrust filings in E.D. Pennsylvania, which is largely due to the many pharmaceutical companies based there, and the In re: Generic Pharmaceuticals Pricing Antitrust Litigation, which is ongoing.
...

Events 11 results

Event | 03.19.13, 12:00 AM UTC - 12:00 AM UTC

Staying Afloat When Your Brand is Under Pressure: How to Avoid, Mitigate and Manage Product Crises

Crowell & Moring’s Advertising & Product Risk Management Group presents our second annual seminar on crisis management.  Legal, business and public relations professionals will examine ways to reduce, and in some cases, eliminate the risk of a product crisis throughout the product lifecycle. From concept design through product launch, our panelists will discuss their approaches to minimizing the risk of product defects, port seizures, advertising claims, and class action litigation.
...

Event | 10.05.11 - 10.06.11, 12:00 AM UTC - 12:00 AM UTC

CMCP 22nd Annual Business Conference

Join us in celebrating 22 years of commitment to diversity and inclusion in California’s legal profession at our upcoming 22nd Annual Business Conference, October 5th-6th, 2011 at the Marriott Hotel, Downtown Los Angeles.
...

Event | 04.22.10 - 04.23.10, 12:00 AM UTC - 12:00 AM UTC

European Generic Medicines Association - Biosimilar Medicines 8th EGA Annual International Symposium

Keith Harrison is one of the speakers at this symposium. The topic is "New US Patient Protection and Affordable Care Act: What’s in for Biosimilars?"
...

Webinars 1 result

Webinar | 12.17.20, 10:00 AM EST - 11:00 AM EST

Trials during COVID – What is happening and choices to be made

Courthouses across the country are restarting and rethinking trials amid the coronavirus pandemic. This webinar will address what actions judges and courts are taking to conduct safe trials, including all virtual proceedings. Crowell & Moring’s experienced trial attorneys will discuss both best practices and important considerations to consider as matters navigate through the system. This panel of experts will weigh in on:
...

Speaking Engagements 6 results